112 related articles for article (PubMed ID: 19622592)
1. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis.
Leyssens B; Wildiers H; Lobelle JP; Gillis A; Paridaens R; Mombaerts I
Ann Oncol; 2010 Feb; 21(2):419-423. PubMed ID: 19622592
[TBL] [Abstract][Full Text] [Related]
2. Management of excessive tearing as a side effect of docetaxel.
Esmaeli B
Clin Breast Cancer; 2005 Feb; 5(6):455-7. PubMed ID: 15748466
[TBL] [Abstract][Full Text] [Related]
3. Epiphora in lung cancer patients receiving docetaxel: a case series.
Yamagishi T; Ochi N; Yamane H; Hasebe S; Takigawa N
BMC Res Notes; 2014 May; 7():322. PubMed ID: 24886618
[TBL] [Abstract][Full Text] [Related]
4. [A Retrospective Analysis of Epiphora Due to Docetaxel].
Noguchi Y; Kawashima Y; Kawara H; Tokuyama Y; Tamura Y; Uchiyama K; Shimizu Y
Gan To Kagaku Ryoho; 2016 Jun; 43(6):737-41. PubMed ID: 27306811
[TBL] [Abstract][Full Text] [Related]
5. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect.
Esmaeli B; Valero V; Ahmadi MA; Booser D
Ophthalmology; 2001 May; 108(5):994-5. PubMed ID: 11320034
[TBL] [Abstract][Full Text] [Related]
6. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity.
Tsalic M; Gilboa M; Visel B; Miller B; Haim N
Med Oncol; 2006; 23(1):57-61. PubMed ID: 16645230
[TBL] [Abstract][Full Text] [Related]
7. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Esmaeli B; Hidaji L; Adinin RB; Faustina M; Coats C; Arbuckle R; Rivera E; Valero V; Tu SM; Ahmadi MA
Cancer; 2003 Aug; 98(3):504-7. PubMed ID: 12879466
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
Esmaeli B; Amin S; Valero V; Adinin R; Arbuckle R; Banay R; Do KA; Rivera E
J Clin Oncol; 2006 Aug; 24(22):3619-22. PubMed ID: 16877729
[TBL] [Abstract][Full Text] [Related]
9. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
Esmaeli B; Hortobagyi GN; Esteva FJ; Booser D; Ahmadi MA; Rivera E; Arbuckle R; Delpassand E; Guerra L; Valero V
Ophthalmology; 2002 Jun; 109(6):1188-91. PubMed ID: 12045065
[TBL] [Abstract][Full Text] [Related]
10. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.
Esmaeli B; Hortobagyi G; Esteva F; Valero V; Ahmadi MA; Booser D; Ibrahim N; Delpassand E; Arbuckle R
Ann Oncol; 2002 Feb; 13(2):218-21. PubMed ID: 11885997
[TBL] [Abstract][Full Text] [Related]
11. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly.
Ahmadi MA; Esmaeli B
Arch Ophthalmol; 2001 Dec; 119(12):1802-4. PubMed ID: 11735790
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction.
Tu AH; Chang EL
Ophthalmology; 2005 Aug; 112(8):1469-71. PubMed ID: 15953639
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.
Chan A; Su C; de Boer RH; Gajdatsy A
J Clin Oncol; 2013 Jun; 31(17):2123-7. PubMed ID: 23650421
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.
Pucci N; Novembre E; Cianferoni A; Lombardi E; Bernardini R; Caputo R; Campa L; Vierucci A
Ann Allergy Asthma Immunol; 2002 Sep; 89(3):298-303. PubMed ID: 12269651
[TBL] [Abstract][Full Text] [Related]
15. The Association Between Taxane Use and Lacrimal Disorders.
McGwin G; Contorno T; Vicinanzo MG; Owsley C
Curr Eye Res; 2023 Sep; 48(9):873-877. PubMed ID: 37232564
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
[TBL] [Abstract][Full Text] [Related]
17. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction.
Mansur C; Pfeiffer ML; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(1):9-12. PubMed ID: 27429222
[TBL] [Abstract][Full Text] [Related]
19. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
